Howdy, Stranger!

It looks like you're new here. If you want to get involved, click one of these buttons!

Alectinib Displays Cutting Edge Terminology - - Now We Get Into The Action

All bisphosphonate therapies have ��warnings�� for use in patients with severe renal impairment. Clinical trial results have shown that even in elderly, frail, osteoporotic patients with renal impairment, intravenous bisphosphonate therapy administration in accordance with the prescribing information did not result in long-term renal function decline. Physicians should follow guidelines for bisphosphonate therapies administration at all times. ? 2013 American Society for Bone and Mineral Research. Osteoporosis is a major public health Selleck Osimertinib concern with rising prevalence resulting from the increasing longevity in many regions.[1] A number of pharmacological options are available for the management of osteoporosis. They include bisphosphonates (alendronate, ibandronate, risedronate, and zoledronic acid), estrogens (estrogen and/or hormone therapy), estrogen agonist/antagonist (raloxifene), parathyroid hormone (PTH[1�C34], teriparatide), and the receptor activator of NF-��B (RANK) ligand inhibitor, denosumab.[2] Available in both oral and parenteral preparations, bisphosphonates are widely regarded as the drug class of choice for the prevention of fractures in postmenopausal women.[1] This class of drug constitutes the focus of this review. Bisphosphonates effectively reduce fracture risk and have a high benefit-to-risk ratio for the treatment of osteoporosis. Bisphosphonates are commonly used in an aged population who often Everolimus present with concomitant kidney diseases Protein Tyrosine Kinase inhibitor or age-related reductions in estimated glomerular filtration rate (eGFR). Given that bisphosphonates are eliminated from the body through the kidneys, it is important to understand the effect of long-term use of bisphosphonates on renal function. A U.S. Food and Drug Administration (FDA) safety newsletter reported 24 cases of renal impairment and acute renal failure between April 2007 and February 2009, associated with the use of zoledronic acid 5?mg in patients with osteoporosis.[3] A second FDA drug safety communication reported an additional 11 cases of fatal acute renal failure and nine cases of renal injury requiring dialysis after zoledronic acid infusion between March 2009 and April 2011.[4] Subsequently, the prescribing information for zoledronic acid 5?mg was revised to include postmarketing surveillance data to reinforce existing warnings regarding renal safety, and to add a statement that zoledronic acid 5?mg is contraindicated in patients with creatinine clearance (CrCl) <35?mL/min and in those with evidence of acute renal impairment (the FDA accepted eGFR calculated by the Cockcroft-Gault formula[5] in lieu of a 24-hour urine collection for calculation of GFR by CrCl).</div>
Sign In or Register to comment.